PDF(Pubmed)
Abstract：
UNASSIGNED: Combination therapy was associated with an increased risk of drug- drug interactions (DDIs) in patients with type 2 diabetes mellitus (T2DM). The present study aimed to investigate the epidemiology of potential DDIs (pDDIs), including potential chemical drug-drug interactions (pCDIs) and potential herb-drug interactions (pHDIs), and classify the influencing factors of pDDIs in these patients.
UNASSIGNED: A retrospective study of the epidemiology of pDDIs among T2DM hospitalized patients older than 18 years and treated with at least two drugs during hospitalization was conducted over a 12-month period in 2019. PDDIs were identified with C (monitor therapy), D (consider therapy modification), and X (avoid combination) risk ratings. Binary logistic regression was used to analyze the risk factors of pDDIs.
UNASSIGNED: A total of 6796 pDDIs were identified from 737 T2DM hospitalized patients during hospitalization, with 0.87% classified as X risk rating, 13.39% as D risk rating. Additionally, 1753 pDDIs were identified after discharge, with 0.11% as X and 25.73% as D risk rating. The drug-drug association networks showed that the majority of pCDIs were associated with cardiovascular system drugs. Chlorphenamine-potassium chloride and danshen-warfarin were the most prevalent interacting pairs of pCDIs and pHDIs with X rating during hospitalization. Multivariate analysis indicated that the likelihood of developing over 4 pDDIs was significantly higher among T2DM patients who had received over 8 medications. The presence of pDDIs after discharge was strongly associated with the complications of T2DM and the number of discharge medications.
UNASSIGNED: T2DM patients were frequently exposed to pDDIs, including pCDIs and pHDIs, both during hospitalization and after discharge. Multi-drug combination was the primary risk factor for pDDIs. Strategies such as enhancing the monitoring and warning for pDDIs, increasing clinical pharmacological experience, as well as developing universally applicable clinical guidelines for pDDIs may be beneficial in reducing the incidence of potentially harmful drug-combinations.
UNASSIGNED: A retrospective study of the epidemiology of pDDIs among T2DM hospitalized patients older than 18 years and treated with at least two drugs during hospitalization was conducted over a 12-month period in 2019. PDDIs were identified with C (monitor therapy), D (consider therapy modification), and X (avoid combination) risk ratings. Binary logistic regression was used to analyze the risk factors of pDDIs.
UNASSIGNED: A total of 6796 pDDIs were identified from 737 T2DM hospitalized patients during hospitalization, with 0.87% classified as X risk rating, 13.39% as D risk rating. Additionally, 1753 pDDIs were identified after discharge, with 0.11% as X and 25.73% as D risk rating. The drug-drug association networks showed that the majority of pCDIs were associated with cardiovascular system drugs. Chlorphenamine-potassium chloride and danshen-warfarin were the most prevalent interacting pairs of pCDIs and pHDIs with X rating during hospitalization. Multivariate analysis indicated that the likelihood of developing over 4 pDDIs was significantly higher among T2DM patients who had received over 8 medications. The presence of pDDIs after discharge was strongly associated with the complications of T2DM and the number of discharge medications.
UNASSIGNED: T2DM patients were frequently exposed to pDDIs, including pCDIs and pHDIs, both during hospitalization and after discharge. Multi-drug combination was the primary risk factor for pDDIs. Strategies such as enhancing the monitoring and warning for pDDIs, increasing clinical pharmacological experience, as well as developing universally applicable clinical guidelines for pDDIs may be beneficial in reducing the incidence of potentially harmful drug-combinations.
摘要：
■联合治疗与2型糖尿病（T2DM）患者的药物相互作用（DDI）风险增加相关。本研究旨在调查潜在DDI(PDDI)的流行病学，包括潜在的化学药物相互作用（pCDIs）和潜在的草药-药物相互作用（pHDIs），并对这些患者pDDIs的影响因素进行分类。
在2019年的12个月期间，对18岁以上的T2DM住院患者中pDDIs的流行病学进行了回顾性研究。用C（监测治疗）鉴定PDDI，D（考虑治疗修改），和X（避免组合）风险评级。采用二元Logistic回归分析pDDI的危险因素。
■在住院期间，共从737名T2DM住院患者中发现6796名pDDIs，0.87%被列为X风险评级，13.39%为D级风险评级。此外,1753pDDIs在出院后被确认，0.11%为X，25.73%为D风险评级。药物-药物关联网络显示大多数pCDI与心血管系统药物相关。氯苯那敏-氯化钾和丹参-华法林是住院期间最普遍的pCDIs和pHDIs相互作用对，评分为X。多变量分析表明，在接受超过8种药物治疗的T2DM患者中，发生超过4pDDI的可能性明显更高。出院后pDDIs的存在与T2DM的并发症和出院药物的数量密切相关。
■T2DM患者经常暴露于pDDIs，包括pCDI和pHDI，住院期间和出院后。多药联合用药是pDDIs的主要危险因素。加强对DDI的监测和预警等策略，增加临床药理经验，以及制定普遍适用的pDDIs临床指南可能有助于降低潜在有害药物组合的发生率。
在2019年的12个月期间，对18岁以上的T2DM住院患者中pDDIs的流行病学进行了回顾性研究。用C（监测治疗）鉴定PDDI，D（考虑治疗修改），和X（避免组合）风险评级。采用二元Logistic回归分析pDDI的危险因素。
■在住院期间，共从737名T2DM住院患者中发现6796名pDDIs，0.87%被列为X风险评级，13.39%为D级风险评级。此外,1753pDDIs在出院后被确认，0.11%为X，25.73%为D风险评级。药物-药物关联网络显示大多数pCDI与心血管系统药物相关。氯苯那敏-氯化钾和丹参-华法林是住院期间最普遍的pCDIs和pHDIs相互作用对，评分为X。多变量分析表明，在接受超过8种药物治疗的T2DM患者中，发生超过4pDDI的可能性明显更高。出院后pDDIs的存在与T2DM的并发症和出院药物的数量密切相关。
■T2DM患者经常暴露于pDDIs，包括pCDI和pHDI，住院期间和出院后。多药联合用药是pDDIs的主要危险因素。加强对DDI的监测和预警等策略，增加临床药理经验，以及制定普遍适用的pDDIs临床指南可能有助于降低潜在有害药物组合的发生率。
